About 15 years ago, while riding on a shuttle bus at the annual American Academy of Dermatology meeting, I overheard two elderly dermatologists discussing the state of dermatology, as they perceived it. One gentleman commented that he had not seen a single advance to rival the advent of tetracycline for acne, and that most of the new treatments did not work very well. At the time, I remember thinking that these practitioners were out of touch with all of the hot new therapies for skin disorders. Since that time, as I have been bombarded by myriad new and supposedly revolutionary "advances," I, too, am beginning to question whether we should equate the concept of "newness"
FDA implements updated iPLEDGE REMS requirements for isotretinoin, allowing at-home pregnancy testing and reducing prescription and counseling burdens.